Kiniksa Pharmaceuticals International (KNSA) Total Current Liabilities (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Total Current Liabilities for 10 years, with the latest figure at $156.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 61.01% year-over-year to $156.6 million; the trailing twelve-month figure through Mar 2026 stood at $156.6 million (up 61.01% YoY), and the FY2025 full-year result was $139.2 million, up 38.33% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $156.6 million, up from $139.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $156.6 million in Q1 2026, with the low at $36.6 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $81.1 million across 5 years, with a median of $64.2 million in 2024.
• Annual changes were most pronounced in 2023 — Total Current Liabilities decreased 27.34% — and 2024, when it surged 79.46%.
• Kiniksa Pharmaceuticals International's Total Current Liabilities stood at $47.1 million in 2022, then soared by 35.27% to $63.7 million in 2023, then surged by 58.05% to $100.6 million in 2024, then surged by 38.33% to $139.2 million in 2025, then rose by 12.52% to $156.6 million in 2026.
• The last three Total Current Liabilities figures came in at $156.6 million (Q1 2026), $139.2 million (Q4 2025), and $123.6 million (Q3 2025), per Business Quant data.